PL3842436T3 - Kompozycje farmaceutyczne zawierające imidazopirymdynę lub pochodne imidazotriazyny do zastosowania w leczeniu schizofrenii - Google Patents

Kompozycje farmaceutyczne zawierające imidazopirymdynę lub pochodne imidazotriazyny do zastosowania w leczeniu schizofrenii

Info

Publication number
PL3842436T3
PL3842436T3 PL20216929.8T PL20216929T PL3842436T3 PL 3842436 T3 PL3842436 T3 PL 3842436T3 PL 20216929 T PL20216929 T PL 20216929T PL 3842436 T3 PL3842436 T3 PL 3842436T3
Authority
PL
Poland
Prior art keywords
imidazopyrimidine
schizophrenia
treatment
pharmaceutical compositions
imidazotriazine
Prior art date
Application number
PL20216929.8T
Other languages
English (en)
Inventor
Chun Eung Park
Young Koo JANG
Yong Je Shin
Ji Yeon Kim
Seung Mo HAM
Yong Gil Kim
Hye Kyung Min
Soo Bong CHA
Hyo Jun Jung
Ju Young Lee
Seung Nam Han
Jin Yong Chung
Eun Ju Choi
Chan Mi Joung
Jong Sil Park
Ji Won Lee
Nahm Ryune Cho
Eun Ju Ryu
Cheol Young Maeng
Original Assignee
Sk Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co., Ltd. filed Critical Sk Biopharmaceuticals Co., Ltd.
Publication of PL3842436T3 publication Critical patent/PL3842436T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20216929.8T 2015-02-26 2016-02-25 Kompozycje farmaceutyczne zawierające imidazopirymdynę lub pochodne imidazotriazyny do zastosowania w leczeniu schizofrenii PL3842436T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150027395 2015-02-26

Publications (1)

Publication Number Publication Date
PL3842436T3 true PL3842436T3 (pl) 2024-03-04

Family

ID=56788906

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16755910T PL3262047T3 (pl) 2015-02-26 2016-02-25 Pochodne imidazopirymidyny i imidazotriazyny i kompozycje farmaceutyczne je zawierające
PL20216929.8T PL3842436T3 (pl) 2015-02-26 2016-02-25 Kompozycje farmaceutyczne zawierające imidazopirymdynę lub pochodne imidazotriazyny do zastosowania w leczeniu schizofrenii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16755910T PL3262047T3 (pl) 2015-02-26 2016-02-25 Pochodne imidazopirymidyny i imidazotriazyny i kompozycje farmaceutyczne je zawierające

Country Status (21)

Country Link
US (6) US9745310B2 (pl)
EP (2) EP3262047B1 (pl)
JP (1) JP6692367B2 (pl)
KR (1) KR102577178B1 (pl)
CN (1) CN107635994B (pl)
AR (1) AR103769A1 (pl)
AU (1) AU2016224227B2 (pl)
BR (1) BR112017018192B1 (pl)
CA (1) CA2976422C (pl)
CL (1) CL2017002163A1 (pl)
DK (2) DK3262047T3 (pl)
ES (2) ES2964324T3 (pl)
FI (1) FI3842436T3 (pl)
IL (1) IL254070B (pl)
MX (1) MX381323B (pl)
PL (2) PL3262047T3 (pl)
PT (2) PT3262047T (pl)
RU (1) RU2710556C2 (pl)
TW (1) TWI713497B (pl)
WO (1) WO2016137260A1 (pl)
ZA (1) ZA201705333B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713497B (zh) 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
CA3155013A1 (en) * 2019-10-21 2021-04-29 Ki Ho Lee Use of imidazopyrimidine or imidazotriazine compound for prevention, alleviation, or treatment of developmental disability
CA3155209A1 (en) 2019-10-21 2021-04-29 Chan Mi Joung Use of imidazopyrimidine or imidazotriazine compounds for prevention, alleviation, or treatment of cognitive disorders, or for improving cognitive function
WO2026072192A1 (en) 2024-09-27 2026-04-02 Alto Neuroscience, Inc. Effective treatment of depression in patients having poor cognition or impaired learning and/or memory with a mglur5 positive allosteric modulator

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4056589B2 (ja) * 1996-07-19 2008-03-05 武田薬品工業株式会社 複素環化合物、その製造法および用途
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
CN1934094A (zh) * 2004-03-05 2007-03-21 万有制药株式会社 二芳基取代杂环5元环衍生物
JP5048675B2 (ja) * 2005-09-27 2012-10-17 エフ.ホフマン−ラ ロシュ アーゲー mGluR2アンタゴニストとしてのオキサジアゾリルピラゾロ−ピリミジン類
RS54510B1 (sr) * 2006-11-22 2016-06-30 Incyte Holdings Corporation Imidazotriazini i imidazopirimidini kao inhibitori kinaze
KR20100033981A (ko) 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
EP2421370A4 (en) 2009-04-23 2012-12-12 Merck Sharp & Dohme 2-alkyl-piperidine-mGluR5 receptor MODULATORS
AR078172A1 (es) * 2009-09-15 2011-10-19 Sanofi Aventis Fenoximetil dihidro oxazolopirimidinonas sustituidas y uso de las mismas como moduladores de receptores metabotropicos de mglur
RU2012116124A (ru) 2009-09-21 2013-10-27 Вандербилт Юниверсити О-БЕНЗИЛ НИКОТИНАМИДНЫЕ АНАЛОГИ КАК ПОЗИТИВНЫЕ АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ mGluR5
ES2443578T3 (es) * 2009-12-29 2014-02-19 Eli Lilly And Company Compuestos de tetrahidrotriazolopiridina como potenciadores de receptores selectivos de mGlu5 útiles para el tratamiento de la esquizofrenia
US8785481B2 (en) * 2010-09-29 2014-07-22 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
WO2012078817A1 (en) 2010-12-08 2012-06-14 Vanderbilt University Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors
JP2013545822A (ja) * 2010-12-17 2013-12-26 ヴァンダービルト ユニバーシティー mGluR5受容体のアロステリック調節剤としての、二環式トリアゾールラクタムおよびピラゾールラクタム
KR101548443B1 (ko) * 2011-02-23 2015-08-28 화이자 인코포레이티드 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
WO2012125732A1 (en) * 2011-03-15 2012-09-20 Vanderbilt University Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors
HK1203412A1 (en) * 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) * 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
TWI713497B (zh) 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物

Also Published As

Publication number Publication date
CA2976422A1 (en) 2016-09-01
AU2016224227A1 (en) 2017-08-31
KR20160104579A (ko) 2016-09-05
RU2017131514A (ru) 2019-03-26
BR112017018192A2 (pt) 2018-04-17
JP2018506561A (ja) 2018-03-08
CA2976422C (en) 2023-09-26
BR112017018192B1 (pt) 2023-11-21
RU2710556C2 (ru) 2019-12-27
JP6692367B2 (ja) 2020-05-13
TWI713497B (zh) 2020-12-21
ES2854288T3 (es) 2021-09-21
US20170349597A1 (en) 2017-12-07
RU2017131514A3 (pl) 2019-05-31
US20240352023A1 (en) 2024-10-24
WO2016137260A1 (en) 2016-09-01
US20210300933A1 (en) 2021-09-30
EP3262047A1 (en) 2018-01-03
US9745310B2 (en) 2017-08-29
EP3842436B1 (en) 2023-11-08
AU2016224227B2 (en) 2020-01-16
ES2964324T3 (es) 2024-04-05
MX2017010630A (es) 2017-11-16
IL254070B (en) 2020-07-30
TW201639848A (zh) 2016-11-16
DK3262047T3 (da) 2021-03-01
EP3842436A1 (en) 2021-06-30
US20190031669A1 (en) 2019-01-31
AR103769A1 (es) 2017-05-31
US12037338B2 (en) 2024-07-16
PL3262047T3 (pl) 2021-05-31
US10100057B2 (en) 2018-10-16
US11046702B2 (en) 2021-06-29
EP3262047B1 (en) 2021-01-06
PT3262047T (pt) 2021-02-25
EP3262047A4 (en) 2018-08-01
US20160251361A1 (en) 2016-09-01
CN107635994B (zh) 2019-11-05
FI3842436T3 (fi) 2024-01-24
HK1244275A1 (zh) 2018-08-03
MX381323B (es) 2025-03-12
US20200277298A1 (en) 2020-09-03
PT3842436T (pt) 2023-12-28
ZA201705333B (en) 2019-07-31
DK3842436T3 (da) 2024-02-05
KR102577178B1 (ko) 2023-09-11
CN107635994A (zh) 2018-01-26
CL2017002163A1 (es) 2018-06-22
IL254070A0 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
IL272820B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
IL276333B (en) Cyclic sulfamoylarylamide history and their use as drugs to treat hepatitis b
IL256085B (en) A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
PL3515420T3 (pl) Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
IL247239A0 (en) Complexes of sirolimus and its derivatives, a process for their preparation and pharmaceutical preparations containing them
IL265970B (en) Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine
PL3842436T3 (pl) Kompozycje farmaceutyczne zawierające imidazopirymdynę lub pochodne imidazotriazyny do zastosowania w leczeniu schizofrenii
EP3148570A4 (en) Pharmaceutical composition for preventing or treating skin rash
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
IL249440B (en) Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases
SI3548006T1 (sl) Sestava za uporabo pri zdravljenju črevesnih sprememb
ZA201607353B (en) Bicyclic derivatives and pharmaceutical composition including the same
EP3322435A4 (en) Pharmaceutical compositions useful for the treatment of tissue injury
GB201513543D0 (en) Compositions for use in the treatment of diabetes
IL257689A (en) Pharmacological preparations and methods for the treatment of diseases associated with hypoxia
GB201603510D0 (en) Compositions for use in the treatment of neurological disease
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
HK40009824A (en) Pharmaceutical composition for use in the treatment of prostate pathologies
GB201714241D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
EP3434271A4 (en) USE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A GAUZE SYTHEM IN POIKILODERMIA
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases